Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Complaints Of Fatigue And Tiredness In People With OSA Improve With CPAP Treatment
A study in the June 15 issue of the Journal of Clinical Sleep Medicine shows that the complaints of fatigue and tiredness in patients with obstructive sleep apnea (OSA) improved significantly with good adherence to continuous positive airway pressure (CPAP) therapy, suggesting that - like the symptom of excessive daytime sleepiness - these complaints are important symptoms of OSA. Don't forget to buy zoloft online no prescription.

Advocacy Group, N.D. Abortion Clinic File Lawsuit To Block State Ultrasound Law
The Red River Women"s Clinic in Fargo, N.D., went to court on Thursday to block a state law from going into effect that would require the clinic to give women the option to view ultrasound images and hear a fetal heartbeat 24 hours before receiving abortion services, the AP/Bismarck Tribune reports. The suit was filed in East Central District Court by the Center for Reproductive Rights on behalf of the clinic, which is the only abortion clinic in North Dakota. In the lawsuit, the clinic asked the court to issue a temporary injunction to prevent the law from taking effect on Aug. 1. A hearing has been scheduled for July 30.Suzanne Stolz, an attorney for CRR, said the law is "unconstitutional"” because it "creates an undue burden on a woman"s right to have an abortion." In a statement, CRR said that the law requires an audible fetal heartbeat consistent with "standard medical practice in the community." However, the Center said no such standard exists. In addition, Stolz said that the North Dakota law is less clear than laws in other states with ultrasound mandates that include a fetal heartbeat provision, including Georgia, Indiana, Kansas, Mississippi, Oklahoma and Wisconsin. Furthermore, CRR said that the equipment needed to provide the audible heartbeat would be expensive for the clinic, although it did not say what the cost would be.Tammi Kromenaker, director of the clinic, said it has offered women the option of viewing an ultrasound image since 2008. She said that the issue with the law is that it is not clear about whether a woman who chooses to view the image must also listen to the fetal heartbeat -- which sometimes cannot be heard in the early stages of pregnancy -- and about the level of technology the clinic must provide.Mary Spaulding Balch, a spokesperson for the National Right to Life Committee, said that the law is not burdensome to women seeking abortions and that it would only require the clinic to use "a simple device used by obstetrician[s] that amplifies" a fetal heartbeat. State Rep. Bette Grande (R), a sponsor of the law, said that the law does not require the Red River clinic to perform the ultrasound. She added that a woman seeking an abortion could receive the image and audio from another clinic prior to the procedure. Grande also noted that the law does not require women to view the ultrasound image and hear the fetal heartbeat -- it "just says they will have this opportunity" (MacPherson, AP/Bismarck Tribune, 7/24).

generic viagra online


News of the day
Future Proofing Equality: Harriet Harman MP To Launch RADAR People Of The Year Awards 2009, UK
The Rt Hon Harriet Harman QC MP, Minister for Women and Equality, will be speaking at the launch of the 2009 RADAR People of the Year (POTY) Awards on Tuesday 16 June at the BT Tower in central London.
Mental Health

Essentialis Meets Primary Endpoint In Phase 2b Trial Of DCCR For Treatment Of Hypertriglyceridemia And Is Granted Extensive Patent Coverage In The US

Essentialis Inc, a clinical stage pharmaceutical company, announced that it met its primary endpoint of statistically significant triglyceride reduction in a 90-patient Phase 2b trial of DCCR in dyslipidemic patients. The study encompassed both patients with very high triglycerides and mixed dyslipidemia and included normal weight, overweight and obese patients presenting with or without hypertension. The randomized, double-blind study, which was powered as if it were pivotal, assessed the drug"s effect on dyslipidemia and evaluated three different doses of DCCR given over an 8-week period compared to placebo. The study included 90 subjects with high and very high triglycerides as well as subjects on stable doses of statins. At the end of 8 weeks, treatment with DCCR resulted in a 30% placebo-adjusted median reduction in triglycerides. The reduction was clinically relevant, highly significant and competitive with existing approved drugs. In subjects with very high baseline triglycerides, DCCR treatment resulted in a substantially greater reduction in triglycerides. In contrast to the effects of Lovaza and fenofibrate - the current gold standard medicines for treating hypertriglyceridemia - no meaningful increase in LDL-C was observed in DCCR-treated subjects, irrespective of baseline triglyceride levels. In subjects with elevated LDL-C at baseline, DCCR treated subjects experienced a fall in LDL-C. Reductions in non-HDL-C and total-C were also observed in DCCR treated subjects together with a modest rise in HDL-C. In subjects on steady doses of statins, the effects of DCCR appeared to be additive to statin therapy. Weight and waist circumference reduction, blood pressure lowering, LFT and insulin resistance improvements were also demonstrated. DCCR was generally well tolerated, and most of the AEs were mild to moderate, resolving without sequelae. There were no SAEs and the discontinuation rate due to AEs was in line with historic lipid-lowering trials. Separately, the company further announced the allowance of a US patent covering DCCR. The patent entitled "Salts of potassium ATP channel openers and uses thereof" contains claims to salts of diazoxide - including DCCR - as well as pharmaceutical formulations of such salts. Additional applications filed in the US and globally will further enhance the patent portfolio of Essentialis. Commenting on these developments, Essentialis President and CEO, Dr Iain Dukes said, "Essentialis has convincingly demonstrated the therapeutic utility of DCCR as a triglyceride lowering agent with a superior profile to existing approved drugs. The issuance of the patent covering DCCR provides timely coverage for its future commercial development." Pivotal phase 3 protocols for very high triglycerides and phase 2 protocols for statin combination therapy are currently being finalized with input from experts and the FDA in parallel with partnering discussions. About DCCR DCCR, diazoxide choline controlled release, is an ATP-dependent potassium channel agonist with potential utility in several cardiovascular and metabolic diseases. Extensive Phase 1 testing and investigator-sponsored clinical studies have demonstrated the drug"s potential to lower triglycerides, non-HDL cholesterol and LDL-cholesterol while raising HDL-cholesterol. In addition, placebo adjusted weight loss exceeding 5% in an 8-week placebo controlled study and 10% in a 6-month study has been demonstrated. Compositions of matter, formulation and method of use patents for DCCR have been filed worldwide. A fixed dose combination product with a statin is under development. About Very High Triglycerides Hypertriglyceridemia, a disease where patients have high blood levels of triglycerides, is associated with increased risk of coronary heart disease even after LDL-cholesterol targets have been achieved. Very high triglycerides are associated with an increased risk of developing pancreatitis. There are approximately 5 million patients in the US with very high triglycerides. The leading products for treating very high triglycerides, Lovaza and fenofibrate, while effective, also cause significant elevations in LDL-cholesterol. About Essentialis Essentialis is a pharmaceutical company based in Carlsbad, CA focused on the development of breakthrough medicines for the treatment of cardiovascular and metabolic diseases. The company"s portfolio of products is targeted at the ATP-sensitive potassium channel, a metabolically-regulated membrane protein whose modulation has the potential to impact a wide range of cardiovascular and metabolic diseases. The company"s lead product has completed Phase 2 studies in dyslipidemic subjects. The company is actively exploring partnering arrangements for DCCR and its portfolio of follow-on and back-up compounds. Essentialis


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009